✦ LIBER ✦

Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study

✍ Scribed by Walther, McClellan M (author);Lyne, J.Chris (author);Libutti, Steven K (author);Linehan, W.Marston (author)

Book ID: 117265779
Publisher: Elsevier BV
Year: 1999
Tongue: English
Weight: 195 KB
Volume: 53
Category: Article
ISSN: 0090-4295
DOI: 10.1016/s0090-4295(98)00562-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Granulocyte/macrophage-colony-stimulatin

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study

✍ Jörg Westermann; Gernot Reich; Joachim Kopp; Ulrike Haus; Bernd Dörken; Antonio 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 143 KB

Sequential administration of interferon

Sequential administration of interferon γ and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial

✍ Manuela Schmidinger; Günther G. Steger; Catharina Wenzel; Gottfried J. Locker; T 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 111 KB

Intratumoral administration of a 1,2-dim

Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma

✍ Evanthia Galanis; Patrick A. Burch; Ronald L. Richardson; Bradley Lewis; Henry C 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB

Interleukin-2, interferon-α, 5-fluoroura

Interleukin-2, interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma : A prospective Phase II study: The experience of Rambam and Lin Medical Centers 1996-2000

✍ Eliahu Gez; Raphael Rubinov; Diana Gaitini; Shimon Meretyk; Lael-Anson Best; Ofe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND The current study evaluated the efficacy and toxicity of interleukin‐2 (IL‐2), interferon‐α (IFN‐α), 5‐fluorouracil (5‐FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). ## METHODS Sixty‐two MRCC patients, median age 63 years, receive

High-dose interleukin-2 for the treatmen

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006

✍ Jacob A. Klapper; Stephanie G. Downey; Franz O. Smith; James C. Yang; Marybeth S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views